Research on men’s health issues in the Department of Urology spans numerous disorders and touches on examining and improving many widely used procedures.
One of the most innovative areas of work done by the Division of Andrology and Urologic Health (AUH) is in the treatment of benign prostatic hyperplasia (BPH). AUH faculty members helped to pioneer the use of Histotripsy, conducting the first clinical trial using the procedure.
The histotripsy procedure was originally developed by HistoSonics (based in Ann Arbor, Michigan) which is developing systems to deliver histotripsy as a non-invasive, image-guided focused ultrasound therapy that mechanically homogenizes target tissue resulting in cellular destruction. Histotripsy technology and intellectual property have been licensed from the University of Michigan. The U-M and several of its faculty hold equity in HistoSonics, including Dr. William Roberts who serves as a co-investigator on the clinical trial.
For more on the work being done by the Department of Urology's Division of AUH, visit the Division's Faculty Profiles.
Prostate Cancer Detection
The Division of AUH has also been involved in the early detection of prostate cancer through the use of urinary biomarkers. This work, supported by the National Cancer Institute and its Early Detection Research Network, seeks to develop clinical practices and symptom indexes that aid in the early detection of prostate and various other cancers.
Dow Health Services Research
Dr. John Wei, of the AUH team, and various other U-M Department of Urology faculty were founding members of the Dow Division of Health Services Research (HSR). This Division is one of the country's preeminent research institutions with respect to clinical and policy-oriented research in the field of urology. The Division is also an integral part of the University’s Institute for Healthcare Policy and Innovation (IHPI), and as such, it is poised to tackle the spectrum of challenges facing patients with urological diseases in the 21st Century.